New combo pill attack targets Hard-to-Treat breast cancer
NCT ID NCT06365788
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests two oral drugs, bicalutamide and abemaciclib, in 53 women with a specific type of advanced breast cancer called androgen receptor-positive triple-negative breast cancer. The goal is to see if the combination can stop the cancer from growing for at least 16 weeks. Researchers will also monitor side effects closely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bicalutamide and abemaciclib (oral tablets)
What this could lead to
If successful, this could offer a new targeted treatment option for a hard-to-treat form of breast cancer that has limited therapies.
What could go wrong
This is an early-phase, single-arm study with only 53 participants, so results may not apply broadly. Side effects from the drug combination could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Antwerp University Hospital
NOT_YET_RECRUITINGAntwerp, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Ghent University Hospital
RECRUITINGGhent, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Jessa Ziekenhuis
RECRUITINGHasselt, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Hospital Brussels
RECRUITINGBrussels, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Hospitals Leuven
RECRUITINGLeuven, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
ZAS Augustinus
RECRUITINGAntwerp, 2610, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact